GlassScriptPhysician profile
Robert R Drouin
NPI 1629168943
$2,062.42
in general payments reported to CMS, 2019-2025
19 companies · $574 in 2025
The $574 reported for 2025 was more than what a typical Physician Assistant provider received nationally (typical 2025 total: $183).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $212 · 2022: $90.08 · 2023: $429 · 2024: $757 · 2025: $574.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,761.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,760.57 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbott Laboratories | $539.42 | 2021-2025 | Cardiomems |
| Novartis Pharmaceuticals Corporation | $257.41 | 2022-2025 | |
| E.R. Squibb & Sons, L.L.C. | $163.97 | 2023-2025 | Eliquis, Camzyos |
| Janssen Pharmaceuticals, INC | $135.31 | 2021-2024 | Xarelto |
| Silk Road Medical, INC. | $124.57 | 2024 | Enroute Transcarotid Neuroprotection System, Enroute Transcarotid Stent, Enroute Enflate Transcarotid Rx Balloon Dilatation Catheter |
| Lantheus Medical Imaging, INC. | $112.93 | 2023-2024 | Definity |
| Boehringer Ingelheim Pharmaceuticals, INC. | $106.89 | 2021-2025 | Jardiance |
| Pfizer INC. | $96.60 | 2021-2023 | |
| Madrigal Pharmaceuticals | $86.91 | 2025 | Rezdiffra |
| Astrazeneca Pharmaceuticals LP | $86.23 | 2021-2024 | Wainua |
| Amgen INC. | $78.55 | 2023-2024 | Repatha |
| Merck Sharp & Dohme LLC | $64.34 | 2022-2025 | Verquvo |
| Amarin Pharma, INC. | $47.83 | 2021 | |
| Kiniksa Pharmaceuticals International, Plc | $39.87 | 2024 | Arcalyst |
| Sanofi-Aventis U.S. LLC | $31.88 | 2022 |
Show all 19 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Zoll Services LLC (A/K/A Zoll Lifecor Corp) | $27.12 | 2025 | Lifevest |
| Bayer Healthcare Pharmaceuticals INC. | $26.84 | 2025 | |
| Alnylam Pharmaceuticals INC. | $19.38 | 2023 | Onpattro |
| United Therapeutics Corporation | $16.37 | 2024 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Robert Drouin listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.